Is LQDA or NAMS more profitable?

LQDA runs the higher net margin — LQDA at 30.74% versus NAMS at -3644.21%.

How have LQDA and NAMS total returns compared?

Over the past 5 years, LQDA delivered 59.01% and NAMS delivered 18.30% annualized total return. Past performance doesn't predict future results.

Liquidia Corporation (LQDA) vs NewAmsterdam Pharma Company N.V. (NAMS)

A side-by-side comparison of Liquidia Corporation and NewAmsterdam Pharma Company N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

LQDA

Liquidia Corporation

$2.30B

$25.91HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

NAMS

NewAmsterdam Pharma Company N.V.

$2.60B

$22.27HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — LQDA vs NAMS

growth of $100 · dividends reinvested · last 6y

LQDA +712.9% (+41.8%/yr)NAMS +114.9% (+13.6%/yr)LQDA compounded faster over this window

LQDA NAMS

LQDA vs NAMS: by the numbers

•NAMS is the larger company ($2.60B vs $2.30B market cap).
•LQDA is profitable (30.74% net margin) while NAMS runs a net loss (-3644.21%).

Metrics side by side

Valuation

Metric	LQDA	NAMS
P/E ratio	18.92	N/A
Forward P/E	10.42	N/A
P/S ratio	5.11	365.60
P/B ratio	11.81	4.12
EV / EBITDA	12.62	N/A
FCF yield	2.63%	N/A

Profitability

Metric	LQDA	NAMS
Gross margin	92.48%	92.15%
Operating margin	-32.45%	-1002.90%
Net margin	30.74%	-3644.21%
ROE	71.04%	-41.10%
ROIC	46.99%	-38.70%

Growth (annualized)

Metric	LQDA	NAMS
Revenue CAGR (5Y)	128.77%	N/A
Total return CAGR (5Y)	59.01%	18.30%

Frequently asked

Is LQDA or NAMS more profitable?: LQDA runs the higher net margin — LQDA at 30.74% versus NAMS at -3644.21%.
How have LQDA and NAMS total returns compared?: Over the past 5 years, LQDA delivered 59.01% and NAMS delivered 18.30% annualized total return. Past performance doesn't predict future results.

Go deeper

Full LQDA analysis Full NAMS analysis Interactive comparison tool

Dig into the metrics

Liquidia P/E ratio Liquidia ROE NewAmsterdam Pharma ROE Liquidia operating margin NewAmsterdam Pharma operating margin Liquidia revenue growth NewAmsterdam Pharma revenue growth Liquidia free cash flow NewAmsterdam Pharma free cash flow

Liquidia & NewAmsterdam Pharma appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.